United States Patent 11,938,099: Tapinarof Atopic Dermatitis Claims, Patent Scope and Competitive Landscape

US Patent No. 11,938,099 is a method-of-treatment patent covering once-daily topical administration of approximately 1.0% tapinarof for mild-to-severe atopic dermatitis. The claims combine the active ingredient, concentration, dosing frequency, disease indication and clinical response. Dependent claims add the oil-in-water formulation, application sites, efficacy endpoints, response timing, durability after treatment cessation and low systemic exposure.

The patent is strategically important because it extends tapinarof protection beyond plaque psoriasis into atopic dermatitis, the indication for which the U.S. Food and Drug Administration approved VTAMA cream in December 2024. Its strongest commercial relevance is likely as an Orange Book-listed method-of-use patent that can support Paragraph IV litigation against generic tapinarof creams seeking an atopic dermatitis indication.

What does US Patent 11,938,099 protect?

The independent claim protects this combination:

Claim element	Required limitation
Disease	Mild to severe atopic dermatitis
Active ingredient	Tapinarof
Concentration	About 1.0%
Route	Topical
Frequency	Once daily
Response	IGA score improves by two grades

Claim 1 is narrower than a general claim to treating atopic dermatitis with tapinarof. An accused product or use must be evaluated against the entire combination. The claim does not expressly require the branded product name, a particular trade formulation, a specific body-surface percentage or a particular treatment duration.

The claim also does not require that the patient achieve an IGA score of 0 or 1. That result appears in claim 15 as a dependent limitation. Claim 1 requires a two-grade improvement, regardless of the final score.

What is the scope of the dependent claims?

The dependent claims divide into five principal protection groups:

Formulation claims: claims 2 and 3.
Anatomic application claims: claim 4.
Clinical-response claims: claims 5 through 8 and 14.
Timing and durability claims: claims 9 through 12.
Systemic-exposure and final-response claims: claims 13 and 15.

Claim 2 requires an oil-in-water emulsion. Claim 3 narrows that emulsion to a specified excipient system. Claims 5 through 8 and 14 cover improvements measured by IGA, itch, EASI, total severity score, body-surface area, sleep and skin symptoms. Claims 9 through 12 specify response at approximately two, four or eight weeks and persistence for approximately four weeks after discontinuation.

How broad is claim 1?

Claim 1 is commercially meaningful but technically constrained. Its breadth comes from the absence of a requirement for the exact excipient composition, a particular body site or a fixed treatment duration. Its limitations come from the required clinical result and the approximately 1.0% concentration.

Concentration limitation

“About 1.0%” will generally be construed in light of the specification, prosecution history and ordinary pharmaceutical formulation practice. The claim does not automatically cover every tapinarof concentration. A product containing 0.5% or 2.0% tapinarof would present a stronger non-infringement position than a product containing a formulation marketed as 1.0% tapinarof.

A generic manufacturer using the same 1.0% strength would face a higher risk under claim 1 than a manufacturer using a materially different strength. That analysis would still depend on whether the generic seeks approval for the patented atopic dermatitis use and whether the proposed labeling directs the claimed method.

Once-daily dosing

The once-daily limitation distinguishes the claim from a formulation used twice daily or on an as-needed basis. A generic label recommending once-daily administration for atopic dermatitis would map directly onto this limitation.

A label that omits the atopic dermatitis indication may reduce inducement risk, but it would not eliminate all exposure. Physicians may prescribe a product off label, and the relevant legal analysis would depend on the product labeling, marketing conduct, available non-infringing uses and evidence of induced infringement.

Two-grade IGA improvement

The two-grade IGA improvement is an outcome limitation. It creates a potential proof issue because the result may vary among patients. Patent infringement does not necessarily require that every patient achieve the claimed outcome. The analysis would typically focus on whether the accused instructions and clinical use cause or are intended to cause the claimed response.

For a generic applicant, the key issue is whether its proposed labeling relies on clinical data demonstrating the same two-grade IGA improvement. If the ANDA label reproduces the reference product’s atopic dermatitis indication and efficacy information, the outcome limitation may be easier for the patent owner to establish.

What formulation is protected by claim 3?

Claim 3 covers a specific oil-in-water emulsion containing the following components:

Phase	Ingredients recited in claim 3
Oil phase	Medium-chain triglycerides; propylene glycol; non-ionic emulsifying wax; diethylene glycol monoethyl ether; polyoxyl stearyl ether-2; polysorbate 80; polyoxyl stearyl ether-20; benzoic acid; butylated hydroxytoluene
Water phase	Sodium citrate; edetate disodium; citric acid monohydrate; water

The claim is narrower than claim 2 because it requires the recited composition architecture and ingredients. A formulation that uses the same ingredients but assigns them to different phases could generate claim-construction and infringement issues. A formulation that substitutes a materially different emulsifier, preservative, chelating agent or solvent may avoid literal infringement of claim 3 while remaining exposed under claim 1 or claim 2.

Claim 3 is most relevant to products that reproduce the commercial tapinarof cream formulation. It is less likely to reach a substantially redesigned generic formulation unless the listed ingredients remain present in the claimed phase structure.

What clinical outcomes are covered by US 11,938,099?

The patent claims multiple efficacy endpoints used in atopic dermatitis development and clinical practice.

Endpoint or result	Claims
Two-grade IGA improvement	1, 15
IGA score of 0 or 1	15
Itch/pruritus NRS improvement by three points	6
EASI improvement of at least 50% or 75%	7
Sleep-quality improvement measured by VAS	8
Improvement in itch, sleep, skin dryness, redness or flaking	5, 14
Response after approximately two, four or eight weeks	9, 11
Continued response for approximately four weeks after treatment ends	10, 12
Systemic tapinarof below the limit of detection	13

The claims use both objective and patient-reported endpoints. EASI and IGA are investigator-assessed measures. Itch NRS and sleep VAS are patient-reported or symptom-based measures.

Claims 10 and 12 are particularly important from a product-positioning standpoint. They cover persistence of improvement after treatment cessation. A label or clinical program that emphasizes durable response could create additional exposure beyond the core once-daily treatment claim.

When does US Patent 11,938,099 expire?

The patent’s enforceable term is governed by the earliest effective non-provisional filing date, statutory patent-term adjustment, terminal disclaimers and any applicable patent-term extension. The grant date is April 2, 2024.

The patent is associated with tapinarof atopic dermatitis treatment rather than the earliest composition protection for tapinarof. Its expected expiration is in the late 2030s, subject to the official USPTO term calculation and any terminal disclaimer. The patent should not be treated as expiring merely 20 years after its issue date.

Item	Assessment
Patent	US 11,938,099 B2
Grant date	April 2, 2024
Technology	Topical tapinarof for atopic dermatitis
Core strength	1.0% tapinarof, once daily, two-grade IGA response
Likely term profile	Late-2030s expiration range, subject to official PTA and terminal-disclaimer data
Regulatory significance	Potential method-of-use protection for VTAMA’s atopic dermatitis indication

An exact expiration date should be taken from the USPTO patent term data and the FDA Orange Book listing if the patent is listed for the relevant NDA. Patent-term analysis should also account for any continuation or terminal-disclaimer relationship with related tapinarof patents.

What is the FDA and Orange Book status of tapinarof?

VTAMA is a topical tapinarof cream developed by Dermavant Sciences for plaque psoriasis. The FDA approved VTAMA cream, 1%, for topical treatment of plaque psoriasis in adults in May 2022. The FDA later approved an expanded indication for topical treatment of mild, moderate and severe atopic dermatitis in adults and pediatric patients two years of age and older in December 2024.[1]

Regulatory item	Status
Product	VTAMA cream, 1%
Active ingredient	Tapinarof
Dosage form	Topical cream
Initial U.S. approval	May 2022
Initial indication	Plaque psoriasis
Atopic dermatitis approval	December 2024
NDA holder at approval	Dermavant Sciences
FDA pathway for generics	ANDA with potential Paragraph IV certification
Relevant patent issue	Method-of-use and formulation protection

The Orange Book analysis depends on whether US 11,938,099 was submitted to FDA for listing against the NDA and whether FDA accepted the listing for the atopic dermatitis indication. Method-of-use patents can be listed when they claim an approved method of using the drug. A patent covering only an unapproved use is not properly listed for that use.

The existence of a patent number alone does not establish current Orange Book listing status. The relevant FDA Orange Book entry, patent-use code and listed expiration date control the regulatory assessment.[2]

How does a Paragraph IV challenge affect generic entry?

A generic applicant seeking approval for the atopic dermatitis indication could address the patent through a Paragraph IV certification. The applicant would assert that the patent is invalid, unenforceable or not infringed. Notice of a Paragraph IV certification can trigger a Hatch-Waxman action within 45 days. A timely suit may impose a 30-month stay on final ANDA approval, subject to statutory exceptions and court rulings.[3]

Potential generic positions include:

Non-infringement

A generic applicant could argue that its proposed use does not satisfy one or more claim limitations, such as:

It does not seek the atopic dermatitis indication.
It does not direct once-daily use.
It uses a concentration outside the scope of “about 1.0%.”
Its labeling does not require or induce a two-grade IGA improvement.
Its formulation does not meet claim 2 or claim 3.
It does not promote or direct treatment after which the claimed durability result occurs.

For a product seeking the same atopic dermatitis indication and 1.0% strength, non-infringement arguments are more difficult under claim 1.

Invalidity

Potential invalidity theories would likely focus on:

Anticipation by prior tapinarof atopic dermatitis studies.
Obviousness based on prior topical aryl hydrocarbon receptor agonists.
Written-description support for the full range of “mild to severe” disease and the claimed clinical outcomes.
Enablement of the full claimed patient population and response limitations.
Indefiniteness relating to “about 1.0%,” “mild to severe,” “improved by two grades” and “below the limit of detection.”

The clinical-response limitations may strengthen patentability if the prosecution record shows that the claimed results were unexpected. They may also create evidentiary disputes over whether the specification supports the full scope of the claims.

Section viii carve-out

If the patent is listed only for a method of use and the generic seeks approval for an unpatented use, a Section viii statement may permit approval without certification to the method-of-use patent. This route is less useful where the generic label includes the patented atopic dermatitis indication or contains instructions that induce the claimed once-daily use.

What patent litigation affects tapinarof?

The principal litigation risk for US 11,938,099 is a future ANDA case rather than a conventional branded-versus-branded dispute. The public record should be reviewed for:

A Paragraph IV notice concerning an ANDA for tapinarof cream.
A complaint filed within 45 days of notice.
A 30-month stay entry in FDA’s approval records.
A district-court judgment on validity or infringement.
A settlement, license or authorized-generic arrangement.
A covenant not to sue or dismissal affecting the patent.

No specific litigation outcome should be inferred solely from issuance of the patent. The patent’s commercial effect will depend on listing, generic filing timing, the scope of the proposed ANDA label and any settlement agreement.

Which companies are challenging tapinarof exclusivity?

The principal commercial parties are:

Company	Role
Dermavant Sciences	Original developer and NDA holder for VTAMA
Roivant Sciences	Parent company associated with Dermavant
Organon	Commercial and strategic counterparty associated with dermatology asset transactions involving VTAMA
Generic manufacturers	Potential ANDA filers and Paragraph IV challengers
FDA	NDA, Orange Book and ANDA regulator
USPTO	Patent grant, term and post-grant authority

Publicly identifiable generic challengers should be confirmed through FDA ANDA records, Paragraph IV notice disclosures and district-court complaints. A generic company is not a confirmed challenger until it files an ANDA certification and provides statutory notice.

How strong is the patent estate for tapinarof?

Tapinarof has a layered protection strategy rather than a single patent dependency.

Protection layer	Commercial purpose	Relevance to US 11,938,099
Active-ingredient or composition patents	Protect tapinarof or pharmaceutical compositions	May create earlier or separate barriers
Formulation patents	Protect cream, emulsion and excipient systems	Claim 3 provides a narrow formulation layer
Method-of-use patents	Protect plaque psoriasis and atopic dermatitis treatment	US 11,938,099 is principally in this category
Clinical-response claims	Protect specified treatment results	Claims 1, 5-15
Regulatory exclusivity	Restrict FDA approval independent of patent validity	Applies by indication and regulatory pathway
Trade secrets	Protect manufacturing and development know-how	May complicate formulation design-around

The estate is strongest against a generic that copies all of the following: 1.0% tapinarof, once-daily administration, the atopic dermatitis indication and the reference product’s clinical-response labeling. The estate is weaker against a product with a different strength, a different dosing schedule or a carved-out label, although other patents may remain relevant.

What manufacturing and formulation barriers exist?

A generic tapinarof cream must demonstrate pharmaceutical equivalence and bioequivalence under the FDA’s applicable topical-product framework. The manufacturer must control:

Tapinarof assay and degradation products.
Particle size and uniformity.
Emulsion stability.
Phase distribution and viscosity.
Preservative and antioxidant performance.
Microbiological quality.
Container-closure compatibility.
Comparative skin permeation or other FDA-required performance measures.

Avoiding claim 3 may require changing the excipient system. That change can create regulatory development costs even if it reduces literal patent exposure. A non-infringing formulation must still match the reference product’s quality and performance requirements.

The manufacturing process itself may create additional IP risk if related patents cover mixing conditions, raw-material specifications, stability or scale-up parameters. Those rights are separate from the treatment claims in US 11,938,099.

How does tapinarof compare with competing atopic dermatitis drugs?

Product	Active ingredient	Route	Indication profile	Competitive patent issue
VTAMA	Tapinarof 1%	Topical cream	Plaque psoriasis and atopic dermatitis	Method-of-use and formulation patents
Eucrisa	Crisaborole 2%	Topical ointment	Atopic dermatitis	Earlier PDE-4 inhibitor estate and generic competition
Opzelura	Ruxolitinib 1.5%	Topical cream	Atopic dermatitis and vitiligo	JAK inhibitor patents, regulatory restrictions
Zoryve	Roflumilast	Topical cream or foam	Dermatologic inflammatory diseases	Formulation, indication and dosage-form patents
Dupixent	Dupilumab	Injectable biologic	Atopic dermatitis and other diseases	Biologic exclusivity and formulation patents
Adbry	Tralokinumab	Injectable biologic	Atopic dermatitis	Biologic patent and regulatory exclusivity

Tapinarof competes with topical nonsteroidal products and biologics. Its once-daily application and nonsteroidal positioning are commercially relevant. US 11,938,099 gives the product an indication-specific patent position against generic topical alternatives, while biologic competitors face different patent and biosimilar frameworks.

What biosimilar risk exists for tapinarof?

Biosimilar risk is not the primary threat to VTAMA. Tapinarof is a small molecule, not a biologic, so competing products would generally enter through the ANDA pathway rather than the biosimilar pathway under section 351(k) of the Public Health Service Act.

The relevant competitive threats are:

Generic tapinarof cream.
Alternative topical nonsteroidal therapies.
Topical JAK inhibitors.
PDE-4 inhibitors.
Oral or injectable systemic therapies.
Physician switching to established biologic products.

The absence of biosimilar exposure does not eliminate competitive pressure. It changes the regulatory route and the expected litigation structure.

What generic launch scenarios exist?

Early at-risk launch

A generic could launch before final resolution if it obtains approval and accepts litigation risk. This scenario would expose the manufacturer to damages, injunctive relief and potential treble damages for willful infringement.

Delayed launch after patent expiry

The generic could wait until the relevant patent expires or until any enforceable injunction ends. This reduces litigation risk but delays market entry.

Carved-out psoriasis or non-AD launch

A generic could seek approval for an unpatented indication while excluding the patented atopic dermatitis use. The commercial value of this route would depend on the remaining label, physician prescribing behavior and other listed patents.

License or settlement

The NDA holder and a first-filer could agree to a licensed entry date, potentially with an authorized generic, supply arrangement or other commercial terms. Settlement terms may remain confidential, while court filings and FDA approval dates may disclose the practical effect.

What is the revenue exposure from US 11,938,099?

The patent’s direct revenue exposure is tied to the atopic dermatitis portion of VTAMA sales, not the full value of tapinarof across all indications. The exposure depends on:

Atopic dermatitis prescription volume.
Pediatric uptake.
Net price and payer coverage.
Duration of therapy.
Generic launch date.
Number of approved generic competitors.
Whether the psoriasis indication remains separately protected.
Whether a generic can use a Section viii carve-out.
Any settlement or authorized-generic structure.

A successful atopic dermatitis generic launch could reduce price and market share rapidly. A carved-out launch would produce a smaller impact if physicians continue prescribing the branded product for the patented use.

Key Takeaways

US 11,938,099 covers once-daily topical treatment of mild-to-severe atopic dermatitis with approximately 1.0% tapinarof.
Claim 1 requires a two-grade improvement in IGA score.
Claims 2 and 3 add oil-in-water emulsion and a detailed excipient composition.
Claims 9 through 12 cover response timing and persistence after treatment cessation.
Claim 13 covers systemic exposure below the limit of detection.
The patent is a method-of-use asset linked to tapinarof’s atopic dermatitis indication.
Generic risk is primarily an ANDA and Paragraph IV issue, not a biosimilar issue.
The highest-risk generic scenario involves a 1.0% tapinarof product with the same once-daily atopic dermatitis label.
Exact patent expiration and Orange Book status must be determined from the live USPTO and FDA records, including any patent-term adjustment, terminal disclaimer and accepted patent-use code.
The patent estate is stronger as a layered portfolio than as a standalone claim set because formulation, method-of-use and regulatory protections may operate together.

FAQs About US Patent 11,938,099 and Tapinarof

Is US 11,938,099 a composition-of-matter patent?

No. Its claims are directed principally to methods of treating atopic dermatitis using topical tapinarof. Claim 3 protects a defined oil-in-water formulation, but the patent is not principally a new-molecule composition-of-matter patent.

Does the patent cover tapinarof for plaque psoriasis?

The quoted claims require atopic dermatitis. They do not expressly cover treatment of plaque psoriasis. Separate tapinarof patents and regulatory protections may apply to psoriasis.

Can a generic avoid the patent by using tapinarof twice daily?

Potentially, if the proposed label genuinely does not direct once-daily administration and does not otherwise induce the claimed method. A different schedule may create clinical, regulatory and other patent issues.

Does a 1.0% tapinarof cream automatically infringe?

No. Product strength alone is insufficient. Infringement requires the claimed method, including the atopic dermatitis indication, once-daily topical administration and the required clinical-response limitation.

Is a tapinarof generic regulated as a biosimilar?

No. Tapinarof is a small molecule. A generic tapinarof cream would ordinarily use the ANDA pathway rather than the 351(k) biosimilar pathway.

References

U.S. Food and Drug Administration. (2022). FDA approves VTAMA cream for plaque psoriasis. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
U.S. Patent and Trademark Office. (2024). United States Patent No. 11,938,099, methods of treating atopic dermatitis. USPTO.
U.S. Food and Drug Administration. (2024). FDA approves tapinarof cream for atopic dermatitis. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TOPICAL TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 11,938,099

Which drugs does patent 11,938,099 protect, and when does it expire?

Summary for Patent: 11,938,099